Skip Navigation
http://ghr.nlm.nih.gov/     A service of the U.S. National Library of Medicine®

RET

Reviewed April 2006

What is the official name of the RET gene?

The official name of this gene is “ret proto-oncogene.”

RET is the gene's official symbol. The RET gene is also known by other names, listed below.

What is the normal function of the RET gene?

The RET gene provides instructions for producing a protein that is involved in signaling within cells. This protein appears to be essential for the normal development of several kinds of nerve cells, including nerves in the intestine (enteric neurons) and the portion of the nervous system that controls involuntary body functions such as heart rate (the autonomic nervous system). The RET protein is also necessary for normal kidney development and the production of sperm (spermatogenesis).

The RET protein spans the cell membrane, so that one end of the protein remains inside the cell and the other end projects from the outer surface of the cell. This positioning of the protein allows it to interact with specific factors outside the cell and to receive signals that help the cell respond to its environment. When growth factors attach to the RET protein, it triggers a complex cascade of chemical reactions inside the cell. These reactions instruct the cell to undergo certain changes, such as dividing or maturing to take on specialized functions.

How are changes in the RET gene related to health conditions?

multiple endocrine neoplasia - caused by mutations in the RET gene

More than 25 mutations in the RET gene are known to cause multiple endocrine neoplasia type 2. Most of these mutations change single protein building blocks (amino acids) in the RET protein. The most common mutation responsible for multiple endocrine neoplasia type 2A substitutes the amino acid arginine for the amino acid cysteine at position 634 (written as Cys634Arg or C634R). Another mutation causes more than 90 percent of cases of multiple endocrine neoplasia type 2B; this change replaces the amino acid methionine with the amino acid threonine at position 918 (written as Met918Thr or M918T). Several amino acid substitutions can cause familial medullary thyroid carcinoma, the third subtype of multiple endocrine neoplasia type 2.

Mutations responsible for multiple endocrine neoplasia type 2 result in an overactive RET protein that can transmit signals without first attaching to growth factors outside the cell. The overactive protein likely triggers cells to grow and divide abnormally, which can lead to the formation of tumors in the endocrine system and other tissues.

other disorders - caused by mutations in the RET gene

Mutations in the RET gene are one cause of Hirschsprung disease, a disorder that causes severe constipation or blockage of the intestine. These genetic changes result in a nonfunctional version of the RET protein that cannot interact with growth factors or transmit signals within cells. Without RET signaling, enteric nerves do not develop properly. Because these nerves control contractions that move stool through the intestine, their absence leads to the intestinal problems characteristic of Hirschsprung disease. The inactivating RET mutations that cause Hirschsprung disease are very different from the overactivating mutations that cause multiple endocrine neoplasia type 2; these two disorders rarely occur in the same individual.

other cancers - associated with the RET gene

Some gene mutations are acquired during a person's lifetime and are present only in certain cells. These changes, which are called somatic mutations, are not inherited. Somatic changes in the RET gene have been identified in several nonhereditary (sporadic) cancers. Chromosomal rearrangements involving the RET gene are one of the most common causes of a sporadic form of thyroid cancer called papillary thyroid carcinoma (also known as RET/PTC). Another type of thyroid cancer, medullary thyroid carcinoma, also can be caused by somatic mutations in the RET gene. In addition, RET mutations have been identified in a small percentage of pheochromocytomas, which are tumors of the adrenal glands that can cause dangerously high blood pressure

Where is the RET gene located?

Cytogenetic Location: 10q11.2

Molecular Location on chromosome 10: base pairs 42,892,532 to 42,944,954

The RET gene is located on the long (q) arm of chromosome 10 at position 11.2.

The RET gene is located on the long (q) arm of chromosome 10 at position 11.2.

More precisely, the RET gene is located from base pair 42,892,532 to base pair 42,944,954 on chromosome 10.

See How do geneticists indicate the location of a gene? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genelocation) in the Handbook.

Where can I find additional information about RET?

You and your healthcare professional may find the following resources about RET helpful.

You may also be interested in these resources, which are designed for genetics professionals and researchers.

What other names do people use for the RET gene or gene products?

  • cadherin family member 12
  • CDHF12
  • MTC1
  • PTC
  • rearranged during transfection
  • RET51
  • RET_HUMAN
  • ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease)
  • RET/PTC

See How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.

What glossary definitions help with understanding RET?

acids ; adrenal glands ; amino acid ; autonomic nervous system ; cancer ; carcinoma ; cell ; cell membrane ; constipation ; contraction ; endocrine system ; enteric ; familial ; gene ; growth factor ; intestine ; involuntary ; kidney ; medullary thyroid carcinoma ; mutation ; neoplasia ; nerve cell ; nervous system ; neuron ; oncogene ; papillary ; pheochromocytoma ; protein ; proto-oncogene ; rearrangement ; somatic mutation ; sperm ; spermatogenesis ; sporadic ; stool ; substitution ; threonine ; thyroid ; tissue ; tumor

You may find definitions for these and many other terms in the Genetics Home Reference Glossary (http://ghr.nlm.nih.gov/glossary).

References
  • Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol. 2003 May;195(2):168-86. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=12652644)
  • Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):441-67. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=15982921)
  • Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=11739416)
  • Gene Review: Hirschsprung Disease (http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=hirschsprung-ov)
  • Gene Review: Multiple Endocrine Neoplasia Type 2 (http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=men2)
  • Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett. 2004 Feb 20;204(2):197-211. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=15013219)
  • Koch CA. Molecular pathogenesis of MEN2-associated tumors. Fam Cancer. 2005;4(1):3-7. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=15883703)
  • Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005 Jun;15(6):531-44. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=16029119)
  • Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005 May;5(5):367-75. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=15864278)
  • Panta GR, Du L, Nwariaku FE, Kim LT. Direct phosphorylation of proliferative and survival pathway proteins by RET. Surgery. 2005 Aug;138(2):269-74. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=16153436)
  • Putzer BM, Drosten M. The RET proto-oncogene: a potential target for molecular cancer therapy. Trends Mol Med. 2004 Jul;10(7):351-7. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=15242684)
  • Santoro M, Carlomagno F, Melillo RM, Fusco A. Dysfunction of the RET receptor in human cancer. Cell Mol Life Sci. 2004 Dec;61(23):2954-64. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=15583857)
  • Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology. 2004 Dec;145(12):5448-51. Epub 2004 Aug 26. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=15331579)
  • Scriver, Charles R; The metabolic & molecular bases of inherited disease; 8th ed.; New York : McGraw-Hill, c2001. p935-938.
  • Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001 Dec;12(4):361-73. Review. (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=Abstract&list_uids=11544105)

 

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.

 
Reviewed: April 2006
Published: January 23, 2009